WO1989002277A3 - Prophylaxie et therapie du syndrome immunodeficitaire acquis - Google Patents

Prophylaxie et therapie du syndrome immunodeficitaire acquis Download PDF

Info

Publication number
WO1989002277A3
WO1989002277A3 PCT/US1988/002970 US8802970W WO8902277A3 WO 1989002277 A3 WO1989002277 A3 WO 1989002277A3 US 8802970 W US8802970 W US 8802970W WO 8902277 A3 WO8902277 A3 WO 8902277A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunodeficiency virus
human immunodeficiency
synthetic peptide
cell
amino acid
Prior art date
Application number
PCT/US1988/002970
Other languages
English (en)
Other versions
WO1989002277A2 (fr
Inventor
Ralph B Arlinghaus
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of WO1989002277A2 publication Critical patent/WO1989002277A2/fr
Publication of WO1989002277A3 publication Critical patent/WO1989002277A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention se rapporte à un procédé servant à produire chez un individu une résistance à l'infection par le virus d'immunodéficience humain. Ledit procédé consiste à vacciner l'individu avec un peptide ou un mélange de peptides synthétiques. Le ou les peptides synthétiques comprennent une séquence d'acides aminés obtenus au moins en partie à partir d'une région conservée d'une protéine d'enveloppe du virus d'immunodéficience humain. Sur présentation sous forme antigénique à un animal, ce peptide induit une immunité véhiculée par lymphocytes dirigée (par exemple une cytotoxicité de lymphocytes T) dans une mesure sensiblement plus grande par rapport à la production d'anticorps dirigée contre le virus d'immunodéficience humain natif qu'il engendre. Le vaccin de la présente invention comprend un peptide synthétique ayant une séquence d'acides aminés obtenue au moins en partie à partir d'épitopes de lymphocytes T d'une région conservée d'une protéine d'enveloppe du virus d'immunodéficience humain et se compose de préférence exclusivement d'épitopes de lymphocytes T.
PCT/US1988/002970 1987-08-28 1988-08-26 Prophylaxie et therapie du syndrome immunodeficitaire acquis WO1989002277A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9064687A 1987-08-28 1987-08-28
US090,646 1987-08-28

Publications (2)

Publication Number Publication Date
WO1989002277A2 WO1989002277A2 (fr) 1989-03-23
WO1989002277A3 true WO1989002277A3 (fr) 1989-05-18

Family

ID=22223672

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/002970 WO1989002277A2 (fr) 1987-08-28 1988-08-26 Prophylaxie et therapie du syndrome immunodeficitaire acquis

Country Status (2)

Country Link
AU (1) AU2914889A (fr)
WO (1) WO1989002277A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074650A (en) * 1985-06-24 2000-06-13 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US6024964A (en) * 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
DE3937412A1 (de) * 1989-11-10 1991-05-16 Hoechst Ag Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten
US5939074A (en) * 1986-12-30 1999-08-17 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptide antigens
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
ATE134195T1 (de) * 1988-06-10 1996-02-15 United Biomedical Inc Peptidfragmente von hiv
FR2650954B1 (fr) * 1989-08-18 1992-02-28 Pasteur Institut Composition resultant de la reunion d'un epitope b de la glycoproteine d'enveloppe d'un retrovirus du type iv et d'un epitope t issu d'une proteine distincte codee par ce retrovirus et leur application a la production d'anticorps protecteurs contre le sida
CA2025634A1 (fr) * 1989-09-19 1991-03-20 Thomas Fuerst Peptides comprenant des epitopes ctl de proteines de hiv et leur utilisation
US6248574B1 (en) * 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
WO1991009869A1 (fr) * 1990-01-05 1991-07-11 Medical Research Council Fragments de la proteine du noyau de vih-1
AU7676891A (en) * 1990-04-03 1991-10-30 Genentech Inc. Hiv envelope polypeptides
AU665023B2 (en) * 1991-08-29 1995-12-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Multideterminant peptide antigens that stimulate helper T lymphocyte response to HIV in a range of human subjects
DK0671947T3 (da) * 1991-12-02 2000-07-24 Univ Texas Præparater til udløsning af cytotoksisk T-lymfocyt-responser mod virus
AU693437B2 (en) * 1993-12-28 1998-07-02 Chiron Mimotopes Pty Ltd T-cell epitopes
CA2181590C (fr) * 1994-01-19 2009-01-06 Frank A. Robey Peptomeres a immunogenicite accrue
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
CA2360347C (fr) 1998-12-31 2013-05-07 Chiron Corporation Expression amelioree de polypeptides hiv et production de particules de type viral
ATE384795T1 (de) 1998-12-31 2008-02-15 Novartis Vaccines & Diagnostic Modifizierte hiv env polypeptide
EP1141314A2 (fr) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides codant pour des polypeptides antigeniques du type c du vih; polypeptides et leurs utilisations
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2002316578A1 (en) 2001-08-31 2003-03-18 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US6455670B1 (en) * 2001-09-06 2002-09-24 Tripep Ab Pentamer peptide amide, ALGPG-NH2, that inhibits viral infectivity and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0203676A2 (fr) * 1985-04-19 1986-12-03 The Wistar Institute Of Anatomy And Biology Vaccin produisant une réponse en cellules T immunogènes protectrice contre un virus
EP0260714A2 (fr) * 1986-09-19 1988-03-23 Oncogen Limited Partnership Utilisation de lymphocytes T actives dans la préparation d'un médicament pour le traitement du SIDA
EP0273716A2 (fr) * 1986-12-30 1988-07-06 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Peptides synthétiques induisant l'immunité cellulaire contre le virus du SIDA et ses protéines
WO1988005440A1 (fr) * 1987-01-16 1988-07-28 Institut Pasteur Peptides ayant des proprietes immunologiques 2-hiv-2
EP0279994A2 (fr) * 1986-12-31 1988-08-31 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Procédé pour prédire des moitiers antisomatogènes reconnues par les T-lymphocytes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0203676A2 (fr) * 1985-04-19 1986-12-03 The Wistar Institute Of Anatomy And Biology Vaccin produisant une réponse en cellules T immunogènes protectrice contre un virus
EP0260714A2 (fr) * 1986-09-19 1988-03-23 Oncogen Limited Partnership Utilisation de lymphocytes T actives dans la préparation d'un médicament pour le traitement du SIDA
EP0273716A2 (fr) * 1986-12-30 1988-07-06 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Peptides synthétiques induisant l'immunité cellulaire contre le virus du SIDA et ses protéines
EP0279994A2 (fr) * 1986-12-31 1988-08-31 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Procédé pour prédire des moitiers antisomatogènes reconnues par les T-lymphocytes
WO1988005440A1 (fr) * 1987-01-16 1988-07-28 Institut Pasteur Peptides ayant des proprietes immunologiques 2-hiv-2

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CELL, Vol. 45, June 1986, B.R. STARCICH et al.: "Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS", see page 637 - page 648, see the whole document. *
FEBS LETTERS, Vol. 218, No. 2, June 1987, M.J.E. STERNBERG et al.: "Prediction of antigenic determinants and secondary structures of the major AIDS virus proteins", see page 231 - page 237, see in particular fig. 3 page 236, "CONCLUSION". *
JOURNAL OF VIROLOGY, Vol. 61, No. 2, February 1987, SUSANNE MODROW et al.: "Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions", see page 570 - page 578, see the whole document. *
NATURE, Vol. 326, April 1987, A.R.M. COATES et al.: ""AIDS Vaccine Predictions"", see page 549 - page 550, see the whole document. *
PROC. NATL. ACAD. SCI. USA, Vol. 84, June 1987, KEMP B. CEASE et al.: "Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide", page 4249-4253, see fig. 1, last 4 lines (envT2) and page 4252, right col. 3rd paragraph. *

Also Published As

Publication number Publication date
WO1989002277A2 (fr) 1989-03-23
AU2914889A (en) 1989-04-17

Similar Documents

Publication Publication Date Title
WO1989002277A3 (fr) Prophylaxie et therapie du syndrome immunodeficitaire acquis
US4474757A (en) Synthetic vaccine and process for producing same
IL91007A0 (en) Synthetic vaccine against aids virus
PT81338A (en) Antigens particularly envelope antigens of the virus of lymphadenopathies and of the acquired immuno-depressive syndrome and virus process for producing virus envelope antigens in the preparation of immunogenic compositions or for the diagnosis of the presence of antibodies against this virus
KR950702839A (ko) 레트로, 인버소-, 및 레트로- 인버소 합성 펩티드 유사체(retro-, inverso-, and retro-inverso synthetic peptide analogues)
EP0328403A3 (fr) Peptides synthétiques relatifs à la protéine HIV-GP120-env. et leur application
EP0109942A3 (en) Immunogenic protein or peptide complex, method of producing said complex and the use thereof as an immune stimulant and as a vaccine
GB2255093A (en) Hiv-1 core protein fragments
ES2007720A6 (es) Procedimiento de obtencion de una vacuna a base de flagelo bacterial.
GB2220939B (en) Peptide fragments of hiv and their use in vaccines and diagnosis
Audibert et al. Enhancement by murabutide of the immune response to natural and synthetic hepatitis B surface antigens
GB2250994B (en) Peptide fragments of hiv
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
ES8800273A1 (es) Perfeccionamientos en la fabricacion de conjugados de proteinas portadores de antigenos inmunogenicos para vacunas contra la malaria
LOLEIT et al. Conjugates of synthetic lymphocyte-activating lipopeptides with segments from HIV proteins induce protein-specific antibody formation
EP0327180A3 (fr) Vaccin contenant des polypeptides dérivés du gène de l'enveloppe du virus de l'immunodéficience humaine de type I
GR3003754T3 (fr)
NZ224251A (en) Synthetic rhinovirus (hrv) peptides and vaccines
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
EP0320034A3 (fr) Peptides synthétiques immunologiquement actifs utilisables pour préparer un vaccin contre le paludisme
Mannhalter et al. Immunization of Chimpanzees with Recombinant gp160, but not Infection with Human Immunodeficiency Virus Type 1, Induces Envelope-Specific Thl Memory Cells
PT91600A (pt) Vaccinal polypeptides
JPH05271282A (ja) 環状主要ｈｉｖ中和決定基とｔ細胞刺激エピトープとを含む合成ペプチド

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CH DE DK FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CH DE DK FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642